Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized multicenter investigator-sponsored Phase 2 trial evaluating MaaT033 concomitant to anti-PD1 treatment in advanced lung cancer patients

Next Previous
Trial Profile

A randomized multicenter investigator-sponsored Phase 2 trial evaluating MaaT033 concomitant to anti-PD1 treatment in advanced lung cancer patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MaaT 033 (Primary) ; Cemiplimab
  • Indications Lung cancer; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms IMMUNOLIFE

Most Recent Events

  • 20 Jan 2026 According to MaaT Pharma media release, first patient has been randomized in this study.
  • 17 Sep 2025 According to MaaT Pharma media release, the trial is expected by the sponsor to start in H2 2025.
  • 19 Jun 2025 According to MaaT Pharma media release, this trial is expected by the sponsor to start mid-2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top